Volume 3.40 | Oct 28

Immune Regulation News 3.40, October 28, 2011
     In this issue: Publications | Industry News | Policy News | Events | Jobs
Cell Therapy News Facebook  Immune Regulation News Twitter
TOP STORY
Unravelling the Mysteries of the Natural Killer Within Us
An international team of scientists has discovered more about the critical role Natural Killer cells play in the body’s innate immune response. [Press release from Monash University discussing online prepublication in Nature] Press Release | Abstract

ON150-CASImmunomodulation_645x110a
PUBLICATIONS (Ranked by Impact Factor of the Journal)

Commensal Microbiota and Myelin Autoantigen Cooperate to Trigger Autoimmune Demyelination
Using the relapsing–remitting mouse model of spontaneously developing experimental autoimmune encephalomyelitis, here scientists show that the commensal gut flora—in the absence of pathogenic agents—is essential in triggering immune processes, leading to a relapsing–remitting autoimmune disease driven by myelin-specific CD4+ T cells. [Nature] Abstract

Expression of A20 by Dendritic Cells Preserves Immune Homeostasis and Prevents Colitis and Spondyloarthritis
Here researchers show that mice lacking the ubiquitin-editing molecule A20 specifically in dendritic cells (DCs) spontaneously showed DC activation and population expansion of activated T cells. [Nat Immunol] Abstract

Expression of Type I Interferon by Splenic Macrophages Suppresses Adaptive Immunity During Sepsis
Here, researchers show that TLR4 is the key immune sensing receptor to initiate paralysis of T-cell immunity after bacterial sepsis. [EMBO J] Abstract

Regulatory T Cells Inhibit Acute IFN-γ Synthesis Without Blocking T-Helper Cell Type 1 (Th1) Differentiation via a Compartmentalized Requirement for IL-10
Scientists developed in vitro and in vivo models that enabled the direct test of regulatory T cell regulation of T-helper cell type 1 differentiation. [Proc Natl Acad Sci USA] Abstract

Cd8 Enhancer E8I and Runx Factors Regulate CD8α Expression in Activated CD8+ T Cells
Here researchers demonstrate a unique transcriptional program regulating CD8 expression during CD8+ effector T-cell differentiation. [Proc Natl Acad Sci USA] Abstract

Tetherin Is a Key Effector of the Antiretroviral Activity of Type I Interferon In Vitro and In Vivo
Researchers find that tetherin markedly inhibits the replication of Moloney murine leukemia virus and is required for the antiretroviral activity of IFNα to be fully manifested in vitro. [Proc Natl Acad Sci USA] Abstract

Coordinated Regulation of Lymph Node Vascular–Stromal Growth First by CD11c+ Cells and Then by T and B Cells
Researchers show that blood vascular, lymphatic, and fibroblastic reticular cell growth are coordinately regulated and identify two distinct phases of vascular–stromal growth—an initiation phase, characterized by upregulated vascular–stromal proliferation, and a subsequent expansion phase. [J Immunol] Abstract

The Actin Regulatory Protein HS1 Is Required for Antigen Uptake and Presentation by Dendritic Cells
Scientists show that dendritic cells from HS1−/− mice differentiate normally and display normal LPS-induced upregulation of surface markers and cytokines. [J Immunol] Abstract

NK-Like T Cells and Plasma Cytokines, but Not Anti-Viral Serology, Define Immune Fingerprints of Resilience and Mild Disability in Exceptional Aging
Since immunity is vital to individual fitness, investigators examined immunologic fingerprint(s) of highly functional elders. [PLoS One] Abstract | Press Release

Antibacterial Role for Natural Killer Cells in Host Defense to Bacillus Anthracis
To determine a potential role for natural killer (NK) cells in immunity to B. anthracis, researchers utilized primary human and murine NK cells, in vitro assays, and in vivo NK cell depletion in a murine model of inhalational anthrax. [Infect Immun] Abstract | Press Release

ON123-RSG_ROSETTE_645x110

INDUSTRY NEWS

Biogen Idec and Portola Pharmaceuticals Announce Global Collaboration for Oral Syk Inhibitor Program Targeting Autoimmune and Inflammatory Diseases
Biogen Idec and Portola Pharmaceuticals, Inc. announced that they have entered into an exclusive, worldwide collaboration and license agreement under which both companies will develop and commercialize highly selective, novel oral Syk inhibitors for the treatment of various autoimmune and inflammatory diseases, including rheumatoid arthritis and systemic lupus erythematosus. [Portola Pharmaceuticals, Inc.] Press Release

TxCell Presents Final Positive Results of the Phase I/II Clinical Trial with Antigen-Specific Treg Cells in Crohn’s Disease
TxCell SA announced the presentation of final positive results of the phase I/II study in Crohn’s disease (CATS-1) with its leading product candidate, OvaSave®. [TxCell SA] Press Release

Xencor Initiates Phase I Study of XmAb®5871 Therapeutic Antibody for the Treatment of Autoimmune Diseases; Dual-Targeted Antibody Aims to Treat Lupus and Rheumatoid Arthritis by Suppressing Autoimmune Response
Xencor, Inc. announced the initiation of a Phase 1 clinical trial of XmAb®5871, the company’s therapeutic antibody for the treatment of autoimmune diseases. [Xencor, Inc.] Press Release

Selecta Announces $47.25 Million Financing to Broaden R&D Capabilities and Accelerate Pipeline of Vaccines and Immunotherapies
Selecta Biosciences, Inc. announced that it has secured new funding from RUSNANO, existing investors, and additional new investors. RUSNAO entered as a significant new investor in Selecta in this new $47.25 million financing which will broaden Selecta’s research and development (R&D) capabilities and advance its new class of vaccines and immunotherapies. [Selecta Biosciences, Inc.] Press Release

Activartis Develops Dendritic Cell-Based Therapeutic Cancer Vaccine in Phase II
Activartis GmbH – former Trimed Biotech GmbH – is developing a cancer immunotherapy concept which is currently in phase II clinical trials. [B3C Newswire] Press Release

POLICY NEWS

Government-Owned Inventions; Availability for Licensing (FR Doc No: 2011-27858) [National Institutes of Health, United States]

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

EVENTS
NEW BIT’s 2nd World Congress of Immunodisease and Therapy
November 18-20, 2011
Guangzhou, China

Visit
our events page to see a complete list of events in the immune regulation community.
JOB OPPORTUNITIES

Lab Technologist – Tissue Culture (STEMCELL Technologies)

Research and Development Technologist, hPSC Media (STEMCELL Technologies) 


Scientist (iPSC) (STEMCELL Technologies)

Contract Assay Service Technologist (STEMCELL Technologies) 


Lab Technologist – Pluripotent Stem Cells (STEMCELL Technologies)

Scientist – Pluripotent Stem Cells (STEMCELL Technologies)

Quality Control Technologist – Cell Separation (STEMCELL Technologies)

Principal Scientist, Immune Disease (Takeda Pharmaceutical Company Limited)

Postdoctoral Position in Immunology (Singapore Immunology Network)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally:
United States, Canada, Europe, Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Immune Regulation News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.

Learn more about Immune Regulation News: Archives | Events | Contact Us